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Conclusion For lung cancer patients with COPD, preop-
erative management using LABA or LAMA bronchodila-
tors and smoking cessation can reduce the frequency of 
postoperative pulmonary complications after surgical lung 
resection. LAMA or LABA inhalation might be useful for 
not only perioperative care, but also for the long-term sur-
vival of COPD patients after surgery.
Keywords Chronic obstructive pulmonary disease · 
Long-acting beta-agonist · Long-acting muscarinic 
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Introduction
Chronic obstructive pulmonary disease (COPD) causes 
impaired pulmonary function as a symptom of occlusive 
disorder and is associated with a significantly high inci-
dence of postoperative pulmonary complications, such as 
pneumonia, acute bronchitis, and atelectasis. Many patients 
with COPD have nonspecific airway hyperreactivity, sug-
gesting the possible presence of bronchospasm or latent 
respiratory tract infection. To reduce the risk of postop-
erative complications, efforts should be made to alleviate 
peripheral airway obstruction and to reduce airway secre-
tion [1, 2]. In Japan, with its aging society, the number 
of patients with lung cancer complicated with COPD is 
expected to further increase, while an increased incidence 
of multiple lung cancers makes the perioperative manage-
ment of surgically treated patients with lung cancer very 
important [3]. Because the prognosis of patients with 
lung cancer complicated with COPD is reportedly poor, 
it is important to provide respiratory care not just during 
the perioperative period after pneumonectomy, but also 
for longer periods [4, 5]. The combination of smoking 
Abstract 
Objective This study aimed to investigate whether perio-
perative inhalations of long-acting beta-agonists (LABAs) 
or long-acting muscarinic antagonists (LAMAs) might 
decrease the incidence of postoperative complications in 
lung cancer patients with chronic obstructive pulmonary 
disease (COPD).
Methods We retrospectively analyzed 108 patients with 
COPD who underwent pulmonary resections for primary 
lung cancer at our hospital between January 2013 and Jan-
uary 2016 to determine the association between the inci-
dence of postoperative complications (e.g., prolonged air 
leakage and pneumonia) and the use of LABAs or LAMAs.
Results Thirty patients with COPD experienced postop-
erative complications (27.8%): Fourteen patients had pro-
longed air leakages (more than 7 days), ten patients devel-
oped pneumonia. The frequency of these postoperative 
pulmonary complications was significantly higher among 
the patients with COPD (24/108 cases, 22.2%), compared 
with the frequency among non-COPD patients (15/224 
cases, 6.7%). Inhaled bronchodilators, such as LAMA or 
LABA, were prescribed for 34 of the 108 patients with 
COPD; the remaining 74 patients were not treated with 
bronchodilators. Pulmonary complications were significant 
lower among the LAMA or LABA users (3/34 cases, 8.8%) 
than among the untreated COPD patients (21/74 cases, 
28.4%).
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cessation, respiratory rehabilitation, and the use of long-
acting muscarinic antagonists (LAMAs) or long-acting 
beta-agonists (LABAs) has been reported to alleviate post-
operative complications in patients with lung cancer com-
plicated with COPD [4, 6–11]. The causal factors for air-
way obstruction in COPD are an irreversible decrease in 
elastic alveolar recoil, peripheral airway obstruction, and 
reversible contraction of the airway smooth muscle. The 
relaxation of airway smooth muscle is necessary for the 
resolution of airway obstruction. To treat the pathological 
symptoms of COPD, anticholinergics, which prevent ace-
tylcholine from binding to muscarinic receptors, and beta-2 
agonists are used. Thus, acetylcholine and the muscarinic 
receptor system play important roles in the pathogenesis of 
COPD [2, 12, 13].
Recently developed LABAs are superior to the previous 
ones in terms of their bronchodilation efficacy. The fourth 
edition of the Guidelines for the Diagnosis and Treatment 
of Chronic Obstructive Pulmonary Disease mentions that 
LAMAs and LABAs are comparable with respect to their 
usefulness for inhalation therapy and recommends inhala-
tion therapy with LAMAs or LABAs [13, 14]. In this study, 
we aimed to investigate whether the incidence of postopera-
tive complications during the perioperative period could be 
reduced in patients with lung cancer complicated by COPD 
by not only providing smoking cessation services before 
surgery, but also by initiating the inhalation of LABAs or 
LAMAs.
Patients and methods
We defined ex-smokers as patients who had quit smok-
ing at least 6  months before surgery; current smok-
ers were defined as those who had quit smoking within 
6 months before surgery. Patients with a smoking history 
and a forced expiratory volume in 1 s (FEV1.0) to forced 
vital capacity (FVC) ratio of less than 70% were classi-
fied as COPD patients; the other patients were classified 
as non-COPD patients. Of the 332 patients who under-
went surgical resections for primary lung cancer at our 
hospital between January 2013 and January 2016, the 
medical records of 108 patients who had COPD and a 
smoking history were retrospectively analyzed to deter-
mine the association between the incidence of postop-
erative complications (e.g., prolonged pulmonary fistu-
lae and pneumonia) and the use of LABAs or LAMAs. 
We recommended inhalations to all the patients based on 
the diagnostic criteria of COPD and used them for the 
patients who agreed to the recommendation. The medical 
records of the remaining 224 non-COPD patients were 
also examined for comparison purposes. In addition, the 
use of LABAs or LAMAs started from at least 1 month 
ago of the operation and continued after operation based 
on the fourth edition of the Guidelines for the Diagno-
sis and Treatment of Chronic Obstructive Pulmonary 
Disease.
Results and discussion
Among the 108 COPD patients, there were 86 men 
and 22 women, with a mean age of 69.3  years (range 
46–84  years). The mean Brinkman index was 1172.1 
(range 50–3480). There were 45 current smokers and 63 
ex-smokers. The mean FEV1.0/FVC was 61.4% (range 
26.8–69.9%) (Table  1). The performed surgical proce-
dures were a partial resection in 11 patients, a pulmonary 
segmentectomy in 3 patients, a lobectomy in 92 patients, 
and a pneumonectomy in two patients. The histological 
types were adenocarcinoma in 53 patients, squamous 
Table 1  Clinicopathological characteristics of the study population
Characteristics
 COPD(non-COPD) 108 (224)
 Age (years) 69.3 (46–84)
 Male/female 86/22
















Table 2  Postoperative complications
COPD(108) Non-COPD(224) P value
Prolonged air leakage 14 (13.0%) 9 (4.0%) 0.0055
Pneumonia 10 (9.3%) 6 (2.7%) 0.0188
IP 0 2 0.8196
Arrhythmia 2 4 1
Chylothorax 2 2 0.831
Wound infection 2 3 1
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cell carcinoma in 38 patients, adenosquamous carcinoma 
in 5 patients, large cell neuroendocrine carcinoma in 3 
patients, large cell carcinoma in 4 patients, small cell car-
cinoma in one patient, and pleomorphic carcinoma in 4 
patients (Table 1). There were no surgical or in-hospital 
deaths. Postoperative complications were observed in 30 
patients. The patients received wedge resection are not 
included in these 30 patients. Regarding the incidence of 
pulmonary complications, such as prolonged air leakage 
and pneumonia, 24 patients (22.2%) with COPD and 15 
(6.7%) non-COPD patients experienced complications. 
The incidence was significantly higher among the COPD 
patients than among the non-COPD patients. No signifi-
cance differences in the incidences of arrhythmia, wound 
infection, or other complications were observed between 
the COPD and non-COPD patients (Table  2). The inci-
dence of prolonged air leakage and pneumonia was sig-
nificantly lower among the 34 patients who received 
LABAs or LAMAs (3 patients, 8.8%) than among the 
74 patients who did not receive these drugs (21 patients, 
28.4%) (Table 3 ).
The COPD patients included 45 current smokers; 24 of 
these patients had undergone smoking cessation therapy 
for at least 1 month before surgery, respiratory rehabilita-
tion, and the inhalation of LABAs or LAMAs. Three of 
the twenty-four patients (12.5%) who underwent inhalation 
therapy as part of their preoperative management devel-
oped prolonged air leakages or pneumonia, whereas six of 
the twenty-one current smokers (28.6%) who did not 66 
receive inhalation therapy developed these pulmonary com-
plications. The incidence of pulmonary complications was 
lower among current smokers who had started inhalation 
therapy as part of their preoperative management; however, 
there was no significant difference statistically (Table 3).
In the present study, examining lung cancer patients 
with COPD, preoperative management that included the 
inhalation of LABAs or LAMAs reduced the frequency 
of postoperative pulmonary complications after surgical 
resection. For the reason why complications decrease by 
preoperative inhalation therapy, we think that periopera-
tive sealing tests go well and that drainage of the sputum 
from peripheral airway goes well by inhalation therapy. 
Other possibility was that the inhalation of LABA or 
LAMA prevented the pneumonia at the peripheral lung by 
anti-inflammatory effect. We think that further detailed 
examination will be necessary in future. Whereas, it was 
reported that inhalation therapy is not necessarily effec-
tive as Yamanashi et al. reported. This report shows that 
there was no significant difference about inhalation ther-
apy using corticosteroids (ICSs) [15]. As for the recent 
LABA, effects come out early and effects are high [9, 13, 
14]. However, we think that the accumulation of cases is 
necessary for comparison.
LABA and LAMA inhalants can be adapted for the 
management of perioperative care. For elderly patients 
with lung cancer, especially those with concurrent 
COPD, not only perioperative but also long-term res-
piratory care, including the administration of LABAs or 
LAMAs, might be necessary. Further prospective studies 
may be needed for the long-term survival of lung cancer 
patients with COPD after surgical resections.
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Table 3  (A) Postoperative complications of COPD patients. (B) Postoperative complications of current smoker
A LABA/LAMA No medications P value
Prolonged air leakage + Pneumonia 3/34(8.8%) 21/74(28.4%) 0.0433
Current smoker Ex-smoker P value
Prolonged air leakage + Pneumonia 9/45(20.0%) 15/63(23.8%) 0.8144
B LABA/LAMA No medications P value
Prolonged air leakage + Pneumonia 3/24(12.5%) 6/21(28.6%) 0.3315
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